Bioptigen Unveils the Envisu™ IntraSurgical OCT System for Real-time Imaging During Ophthalmic Surgery
RESEARCH TRIANGLE PARK, NC (PRWEB) April 23, 2014 -- Bioptigen Inc. today unveiled the Envisu IntraSurgical OCT for real-time imaging during ophthalmic surgical procedures. Key attributes of the Envisu IntraSurgical OCT include a wide, flat scan for accurate structural reproduction, and focal controls that operate independently of the microscope. These innovations will provide the surgeon with maximal versatility to assess surface and sub-surface tissue structures during surgical manipulations. Bioptigen’s Envisu IntraSurgical OCT is modularly designed for compatibility with new and existing operating microscopes to extend the power of OCT to surgical ophthalmology.
"This advance brings surgeons one step closer to realizing the full value of intraoperative OCT," said Dr. Eric Buckland, CEO of Bioptigen. “This is the first OCT system offering fully independent focus and zoom control for optimizing images from the cornea to the retina.” Clinical evaluations are planned at Bascom Palmer Eye Institute and other institutions beginning in June 2014.
“We are very excited to use the Bioptigen Envisu IntraSurgical OCT for its initial clinical assessments,” said Sonia H. Yoo, M.D of Bascom Palmer. “The capability to deliver simultaneous OCT and surgical microscope images during DALK and DSAEK cornea transplant procedures addresses an important need in imaging-guided surgery for ophthalmology.”
Bioptigen currently markets the FDA-cleared Envisu C2300 Spectral Domain Ophthalmic Imaging System for handheld and mounted use in clinical and perioperative settings. The new Envisu IntraSurgical OCT is not available for sale. Bioptigen will be showcasing the innovation on an appointment basis during ASCRS, April 26-28 in Boston, MA.
About Bioptigen
Deployed in top ophthalmic research and clinical institutions worldwide, Bioptigen devices are covered by 75-plus patent applications, including 50 awarded patents. More than 300 scientific articles have been published citing data acquired with Bioptigen technologies. Learn more about Bioptigen and its technologies at http://www.bioptigen.com.
Bioptigen Contact:
George Wildeman
Vice President, Business Development
Phone: 1-919-595-1269
Gwildeman(at)bioptigen(dot)com
http://www.bioptigen.com
George Wildeman, Bioptigen, +1 (607) 765-0112, [email protected]
Share this article